Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tuberculosis and HIV infection]

H L Rieder1

  • 1Tuberculosis Section, International Union Against Tuberculosis and Lung Disease, Paris, Frankreich.

Pneumologie (Stuttgart, Germany)
|February 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Armand Van Deun - pioneering public health physician (1953-2023).

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

When to start treatment? Dilemma illustrated by a paediatric case of extensively drug-resistant tuberculosis of the central nervous system.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2020
Same author

Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2019
Same author

Outcome definitions for multidrug-resistant tuberculosis treated with shorter treatment regimens.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2019
Same author

Sputum smear microscopy in the Xpert<sup>®</sup> MTB/RIF era.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2018
Same author

Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2018

Human immunodeficiency virus (HIV) has had a limited impact on tuberculosis in Western Europe due to effective control measures. Preventive therapy with isoniazid is recommended for individuals with dual infections to reduce tuberculosis risk.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Epidemiology

Context:

  • Global tuberculosis (TB) landscape significantly altered by human immunodeficiency virus (HIV).
  • Western Europe has maintained relatively low TB impact despite the HIV epidemic, attributed to decades of control efforts.
  • Potential for HIV to undermine TB control in specific populations, such as injection drug users, requires ongoing monitoring.

Purpose:

  • To assess the impact of HIV on tuberculosis control in Western Europe.
  • To emphasize the continued importance of fundamental TB control principles.
  • To highlight the benefits of preventive isoniazid therapy for co-infected individuals.

Summary:

  • While HIV has profoundly impacted global TB rates, its effect in Western Europe remains contained due to successful control strategies.

Related Experiment Videos

  • Maintaining TB in differential diagnoses and ensuring complete treatment are crucial, regardless of the HIV epidemic's scale.
  • Preventive isoniazid therapy is advised for individuals with both HIV and TB, as it effectively lowers subsequent TB risk.

    • Impact:

    • Reinforces the need for sustained vigilance in TB control measures, even in regions with low HIV impact.
    • Underscores the importance of early diagnosis and complete treatment completion for all tuberculosis cases.
    • Supports the clinical recommendation of isoniazid preventive therapy for HIV-positive individuals to mitigate TB incidence.